Insulin glulisine

Drugs

Volumn 66, Issue 6, 2006, Pages 861-869

  Robinson, Dean M ^a   Wellington, Keri ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENERGIC RECEPTOR STIMULATING AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CORTICOSTEROID; DEXTROPROPOXYPHENE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DISOPYRAMIDE; DIURETIC AGENT; FIBRIC ACID DERIVATIVE; FLUOXETINE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HUMAN GROWTH HORMONE; HUMAN INSULIN; INSULIN GLULISINE; INSULIN LISPRO; ISONIAZID; MONOAMINE OXIDASE INHIBITOR; PENTOXIFYLLINE; PHENOTHIAZINE; PROTEINASE INHIBITOR; SALICYLIC ACID; SULFONAMIDE; THYROID HORMONE;

AREA UNDER THE CURVE; CLINICAL TRIAL; DIABETES MELLITUS; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEART DISEASE; HUMAN; HYPERSENSITIVITY; HYPOGLYCEMIA; INJECTION SITE REACTION; KETOACIDOSIS; REVIEW;

ADULT; AREA UNDER CURVE; CLINICAL TRIALS; DIABETES MELLITUS; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; MOLECULAR SEQUENCE DATA; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 33646776813     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200666060-00011     Document Type: Review

References (30)

1. World Health Organisation. Diabetes action now [online]. Available from URL: http://www.who.int/diabetes/actionnow/en/DANbooklet.pdf [Accessed 2004 Oct 13]
2. Stratton IM, Adler AI, Neil HAW, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321 (7258): 405-12
3. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group [published erratum appears in Lancet 1999 Aug 14; 354 (9178): 602]. Lancet 1998 Sep 12; 352 (9131); 837-53
4. American Diabetes Association. Insulin administration. Diabetes Care 2004 Jan; 27 Suppl. 1: S106-9
5. Vajo Z, Fawcett J, Duckworth WC. Recombinant DNA technology in the treatment of diabetes: insulin analogs. Endocr Rev 2001 Oct; 22 (5): 706-17
6. Dunn CJ, Plosker GL, Keating GM, et al. Insulin glargine: an updated review of its use in the management of diabetes mellitus. Drugs 2003; 63 (16): 1743-78
7. Reynolds NA, Wagstaff AJ. Insulin aspart: a review of its use in the management of type 1 or 2 diabetes mellitus. Drugs 2004; 64 (17): 1957-74
8. Wilde MI, McTavish D. Insulin lispro: a review of its pharmacological properties and therapeutic use in the management of diabetes mellitus. Drugs 1997 Oct; 54 (4): 597-614
9. Aventis Pharmaceuticals Inc. Apidra™ insulin glulisine (rDNA origin) injection [online]. Available from URL: http://www.f-da.gov/cder/foi/ label/2004/021629lbl.pdf [Accessed 2006 Mar 20]
10. Hennige AM, Strack V, Metzinger E, et al. Effects of new insulin analogues HMR1964 (insulin glulisine) and HMR1423 on insulin receptors. Diabetologia 2005 Jul 29; 48: 1891-7
11. Rakatzi I, Ramrath S, Ledwig D, et al. A novel insulin analog with unique properties: Lys(B3), Glu(B29) insulin induces prominent activation of insulin receptor substrate 2, but marginal phosphorylation of insulin receptor substrate 1. Diabetes 2003 Sep; 52 (9): 2227-38
12. Rakatzi I, Seipke G, Eckel J. [LysB3, GluB29] insulin: a novel insulin analog with enhanced β-cell protective action. Biochem Biophys Res Commun 2003 Oct 24; 310 (3): 852-9
13. Hennige AM, Lehmann R, Weigert C, et al. Insulin glulisine: insulin receptor signaling characteristics in vivo. Diabetes 2005 Feb; 54 (2): 361-6
14. Becker RH, Frick AD, Burger F, et al. A comparison of the steady-state pharmacokinetics and pharmacodynamics of a novel rapid-acting insulin analog, insulin glulisine, and regular human insulin in healthy volunteers using the euglycemic clamp technique. Exp Clin Endocrinol Diabetes 2005 May; 113 (5): 292-7
15. Becker RHA, Frick A, Wessels D. Pharmacodynamics and pharmacokinetics of a new, rapidly-acting insulin analog, insulin glulisine [abstract no. 471-P]. Diabetes 2003; 52 Suppl. 1: A110. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans (LA)
16. Nosek L, Becker RHA, Frick AD, et al. Prandial blood glucose control with pre- and post-meal insulin glulisine versus regular human insulin [abstract no. 588-P]. Diabetes 2004; 53 Suppl. 2: A139-140. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4-8; Orlando (FL)
17. Becker RHA, Frick AD, Kapitza CK, et al. Pharmacodynamics (PD) and pharmacokinetics (PK) of insulin glulisine compared with insulin lispro (IL) and regular human insulin (RHI) in patients with type 2 diabetes [abstract no. 503-P]. Diabetes 2004; 53 Suppl. 2: A119. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4-8; Orlando (FL)
18. Becker RH, Frick AD, Burger F, et al. Insulin glulisine, a new rapid-acting insulin analogue, displays a rapid time-action profile in obese non-diabetic subjects. Exp Clin Endocrinol Diabetes 2005 Sep; 113 (8): 435-43
19. Danne T, Becker RH, Heise T, et al. Pharmacokinetics, prandial glucose control, and safety of insulin glulisine in children and adolescents with type 1 diabetes. Diabetes Care 2005 Sep; 28 (9): 2100-5
20. Frick A, Becker RHA, Wessels D, et al. Pharmacokinetic and glucodynamic profiles of insulin glulisine following subcutaneous administration at various injection sites [abstract no. 511-P]. Diabetes 2003; 52 Suppl. 1: A119. Plus poster presented at the 63rd Annual Scientific Sessions of the American Diabetes Association; 2003 Jun 13-17; New Orleans (LA)
21. Gabry KE. Application number: 21-629 (Insulin glulisine). Medical Review [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2004/21- 629_Apidra.htm [Accessed 2004 Oct 15]
22. Frick AD, Scholtz H, Burger F, et al. Absorption of insulin glulisine when mixed with NPH insulin [abstract no. 1329-P]. Diabetes 2004; 53 Suppl. 2: A321. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4-8; Orlando (FL)
23. Jaros M, Martinek V, Piechatzek R, et al. Pharmacokinetics of insulin glulisine in non-diabetic renally impaired patients [abstract no. 1330-P]. Diabetes 2004; 53 Suppl. 2: A321-322. Plus poster presented at the 64th Annual Scientific Sessions of the American Diabetes Association; 2004 Jun 4-8; Orlando (FL)
24. Dreyer M, Prager R, Robinson A, et al. Efficacy and safety of insulin glulisine in patients with type 1 diabetes. Horm Metab Res 2005 Nov; 37 (11): 702-7
25. Garg SK, Rosenstock J, Ways K. Optimized basal-bolus insulin regimens in type 1 diabetes: insulin glulisine versus regular human insulin in combination with basal insulin glargine [published erratum appears in Endocr Pract 2005; 11 (2): 145]. Endocr Pract 2005 Jan-Feb; 11 (1): 11-7
26. Dailey G, Rosenstock J, Moses RWK, et al. Insulin glulisine provides improved glycemic control in patients with type 2 diabetes. Diabetes Care 2004 Oct; 27 (10): 2363-8
27. Pian LP, Sahlroot T. Application number: 21-629 (Insulin glulisine). Statistical review [online]. Available from URL: http://www.fda.gov/cder/foi/ nda/2004/21-629_Apidra.htm [Accessed 2004 Oct 18]
28. Hanaire-Broutin H, Schumicki DM, Hoogma RPL, et al. Safety of insulin glulisine compared with insulin aspart administered by continuous subcutaneous insulin infusion [abstract no. 826]. Diabetologia 2004; 47 Suppl. 1: A298. Plus poster presented at the 40th Annual Meeting of the European Association for the Study of Diabetes; 2004 Sep 5-9; Munich
29. Aventis Pharmaceuticals Inc. Aventis receives FDA approval of its rapid-acting insulin analogue Apidra® [online]. Available from URL: http://www.aventis.com [Accessed 2004 Nov 30]
30. Aventis Pharmaceuticals Inc. Aventis announced European approval for Apidra. [online]. Available from URL: http://www.aventis.com [Accessed 2004 Dec 22]